{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:13:47Z","timestamp":1780424027801,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s11912-020-00946-3","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T01:02:21Z","timestamp":1594429341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunotherapy in Anal Cancer"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0962-0519","authenticated-orcid":false,"given":"Lisa","family":"Phuong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Rajdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"key":"946_CR1","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2016\/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019."},{"key":"946_CR2","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1200\/JCO.2013.52.3464","volume":"32","author":"E Serup-Hansen","year":"2014","unstructured":"Serup-Hansen E, Linnemann D, Skovrider-Ruminski W. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. J Clin Oncol. 2014;32:1812\u20137. https:\/\/doi.org\/10.1200\/JCO.2013.52.3464.","journal-title":"J Clin Oncol"},{"issue":"11","key":"946_CR3","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.2015-0091","volume":"20","author":"VK Morris","year":"2015","unstructured":"Morris VK, Rashid A, Rodriguez-Bigas M, Das P, Chang G, Ohinata A, et al. Clinicopathologic features associated with human papillomavirus\/p16 in patients with metastatic squamous cell carcinoma of the anal canal. Oncologist. 2015;20(11):1247\u201352. https:\/\/doi.org\/10.1634\/theoncologist.2015-0091.","journal-title":"Oncologist."},{"issue":"9","key":"946_CR4","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/bjs.4994","volume":"92","author":"JH Scholefield","year":"2005","unstructured":"Scholefield JH, Castle MT, Watson NF. Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg. 2005;92(9):1133\u20136. https:\/\/doi.org\/10.1002\/bjs.4994.","journal-title":"Br J Surg"},{"key":"946_CR5","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","volume":"14","author":"M Flam","year":"1996","unstructured":"Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527\u201339. https:\/\/doi.org\/10.1200\/JCO.1996.14.9.2527.","journal-title":"J Clin Oncol"},{"key":"946_CR6","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","volume":"30","author":"LL Gunderson","year":"2012","unstructured":"Gunderson LL, Winter KA, Ajani JA. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin. J Clin Oncol. 2012;30:4344\u201351. https:\/\/doi.org\/10.1200\/JCO.2012.43.8085.","journal-title":"J Clin Oncol"},{"key":"946_CR7","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Anal Carcinoma Version 1.2020. 2019 Nov 19;National Comprehensive Cancer Network. Abstract available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/anal.pdf."},{"key":"946_CR8","doi-asserted-by":"publisher","first-page":"viii715","DOI":"10.1093\/annonc\/mdy424.022","volume":"29","author":"S Rao","year":"2018","unstructured":"Rao S, Sclafani F, Eng C, Gr\u00f8nlie Guren M, Adams RA, Benson A, et al. InterAACT: a multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment na\u00efve disease - an International Rare Cancers Initiative (IRCI) trial. Ann Oncol. 2018;29:viii715\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdy424.022.","journal-title":"Ann Oncol"},{"issue":"1","key":"946_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007 Jan;13(1):54\u201361. https:\/\/doi.org\/10.1038\/nm1523.","journal-title":"Nat Med"},{"issue":"9","key":"946_CR10","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007 Sep;13(9):1050\u20139. https:\/\/doi.org\/10.1038\/nm1622.","journal-title":"Nat Med"},{"issue":"4951","key":"946_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1126\/science.2157286","volume":"248","author":"BA Werness","year":"1990","unstructured":"Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248(4951):76\u20139. https:\/\/doi.org\/10.1126\/science.2157286.","journal-title":"Science."},{"key":"946_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","volume":"224","author":"BT Fife","year":"2008","unstructured":"Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166\u201382. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00662.x.","journal-title":"Immunol Rev"},{"key":"946_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","volume":"18","author":"VK Morris","year":"2017","unstructured":"\u2022\u2022 Morris VK, Salem ME, Nimeiri H. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:446\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(17)30104-3. This was the first prospective multicenter single-arm phase II trial evaluating immunotherapy in SCCA and showed that nivolumab monotherapy was effective and well-tolerated in refractory metastatic SCCA.","journal-title":"Lancet Oncol"},{"key":"946_CR14","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","volume":"28","author":"PA Ott","year":"2017","unstructured":"\u2022\u2022 Ott PA, Piha-Paul SA, Munster P. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017;28:1036\u201341. https:\/\/doi.org\/10.1093\/annonc\/mdx029. This multi-cohort phase Ib trial evaluated pembrolizumab for patients with advanced solid malignancies, showing antitumor activity in PD-L1\u2013positive advanced SCCA, as well as a tolerable side effect profile. These encouraging findings have therefore led to continued investigation of pembrolizumab in advanced SCCA.","journal-title":"Ann Oncol"},{"key":"946_CR15","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/1541-7786.MCR-17-0060","volume":"15","author":"V Morris","year":"2017","unstructured":"Morris V, Rao X, Pickering C. Comprehensive genomic profiling of metastatic squamous cell carcinoma of the anal canal. Mol Cancer Res. 2017;15:1542\u201350. https:\/\/doi.org\/10.1158\/1541-7786.MCR-17-0060.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"946_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imr.12132","volume":"257","author":"CS Hinrichs","year":"2014","unstructured":"Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56\u201371. https:\/\/doi.org\/10.1111\/imr.12132.","journal-title":"Immunol Rev"},{"key":"946_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/bjc.2015.448","volume":"114","author":"DC Gilbert","year":"2016","unstructured":"Gilbert DC, Serup-Hansen E, Linnemann D, H\u00f8gdall E, Bailey C, Summers J, et al. Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. Br J Cancer. 2016;114:134\u20137. https:\/\/doi.org\/10.1038\/bjc.2015.448.","journal-title":"Br J Cancer"},{"key":"946_CR18","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","volume":"33","author":"S Stevanovic","year":"2015","unstructured":"Stevanovic S, Draper LM, Langhan MM. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33:1543\u201350. https:\/\/doi.org\/10.1200\/JCO.2014.58.9093.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"946_CR19","doi-asserted-by":"publisher","first-page":"Abstract 3009","DOI":"10.1200\/JCO.2017.35.15_suppl.3009","volume":"35","author":"CS Hinrichs","year":"2017","unstructured":"Hinrichs CS, Doran SL, Stevanovic S. A phase I\/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers [abstract]. J Clin Oncol. 2017;35(Suppl):Abstract 3009. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.3009.","journal-title":"J Clin Oncol"},{"key":"946_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40661-017-0046-9","volume":"4","author":"BA Miles","year":"2017","unstructured":"Miles BA, Monk BJ, Safran HP. Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy. Gynecol Oncol Res Pract. 2017;4:9. https:\/\/doi.org\/10.1186\/s40661-017-0046-9.","journal-title":"Gynecol Oncol Res Pract"},{"key":"946_CR21","doi-asserted-by":"publisher","unstructured":"Huh WK, Dizon DS, Powell MA. ADXS11\u2013001 immunotherapy in squamous or non-squamous persistent\/recurrent metastatic cervical cancer: results from stage I of the phase II GOG\/NRG0265 study [abstract]. J Clin Oncol. 2016; 34(Suppl):Abstract 5516. Doi: https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.5516.","DOI":"10.1200\/JCO.2016.34.15_suppl.5516"},{"issue":"Suppl 5","key":"946_CR22","doi-asserted-by":"publisher","first-page":"Abstract 537P","DOI":"10.1093\/annonc\/mdx393.063","volume":"28","author":"C Eng","year":"2017","unstructured":"\u2022 Eng C, Fakih M, Armin M. P2 study of ADXS11\u2013001 immunotherapy in patients with persistent\/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer [abstract]. Ann Oncol. 2017;28(Suppl 5):Abstract 537P. https:\/\/doi.org\/10.1093\/annonc\/mdx393.063. This single-arm phase II study of ADXS11\u2013011 monotherapy showed activity, such that it met the pre-defined 6-month PFS rate, and was overall well-tolerated in metastatic SCCA.","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"946_CR23","doi-asserted-by":"publisher","first-page":"Abstract e15072","DOI":"10.1200\/JCO.2017.35.15_suppl.e15072","volume":"35","author":"H Safran","year":"2017","unstructured":"Safran H, Leonard KL, DiPetrillo TA. ADXS11\u2013001 Lm-LLO immunotherapy, mitomycin, 5-fluorouracil (5-FU) and intensity-modulated radiation therapy (IMRT) for anal cancer [abstract]. J Clin Oncol. 2017;35(Suppl):Abstract e15072. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.e15072.","journal-title":"J Clin Oncol"},{"key":"946_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/978-3-030-03502-0_7","volume":"177","author":"CJ Wang","year":"2019","unstructured":"Wang CJ, Palefsky JM. HPV-associated anal cancer in the HIV\/AIDS patient. Cancer Treat Res. 2019;177:183\u2013209. https:\/\/doi.org\/10.1007\/978-3-030-03502-0_7.","journal-title":"Cancer Treat Res"},{"issue":"7","key":"946_CR25","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","volume":"5","author":"M Cook","year":"2019","unstructured":"\u2022 Cook M, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced stage cancer: a systematic review. JAMA Oncol. 2019;5(7):1049\u201354. https:\/\/doi.org\/10.1001\/jamaoncol.2018.6737. A systematic review of HIV\/AIDS patients demonstrated that there was no change in the safety profile of immunotherapy in advanced-stage cancer. Additional clinical trials would be beneficial in studying safety and efficacy of immune checkpoint inhibitors in SCCA.","journal-title":"JAMA Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-00946-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-020-00946-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-00946-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:02:26Z","timestamp":1659092546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-020-00946-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["946"],"URL":"https:\/\/doi.org\/10.1007\/s11912-020-00946-3","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,11]]},"assertion":[{"value":"11 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"94"}}